» Articles » PMID: 30109812

Novel Isatin-derived Molecules Activate P53 Via Interference with Mdm2 to Promote Apoptosis

Abstract

The p53 protein is a key tumor suppressor in mammals. In response to various forms of genotoxic stress p53 stimulates expression of genes whose products induce cell cycle arrest and/or apoptosis. An E3-ubiquitin ligase, Mdm2 (mouse-double-minute 2) and its human ortholog Hdm2, physically interact with the amino-terminus of p53 to mediate its ubiquitin-mediated degradation via the proteasome. Thus, pharmacological inhibition of the p53-Mdm2 interaction leads to overall stabilization of p53 and stimulation of its anti-tumorigenic activity. In this study we characterize the biological effects of a novel class of non-genotoxic isatin Schiff and Mannich base derivatives (ISMBDs) that stabilize p53 on the protein level. The likely mechanism behind their positive effect on p53 is mediated via the competitive interaction with Mdm2. Importantly, unlike Nutlin, these compounds selectively promoted p53-mediated cell death. These novel pharmacological activators of p53 can serve as valuable molecular tools for probing p53-positive tumors and set up the stage for development of new anti-cancer drugs.

Citing Articles

p53: The Multifaceted Roles of Covalent Modifications in Cancer.

Grigoreva T, Romanova A, Tribulovich V, Pestov N, Oganov R, Kovaleva D Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770524 PMC: 11677429. DOI: 10.3390/ph17121682.


From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.

Ahmadi S, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M Biomark Res. 2024; 12(1):137.

PMID: 39538363 PMC: 11565275. DOI: 10.1186/s40364-024-00676-9.


Ubiquitin recruiting chimera: more than just a PROTAC.

Grigoreva T, Novikova D, Melino G, Barlev N, Tribulovich V Biol Direct. 2024; 19(1):55.

PMID: 38978100 PMC: 11232244. DOI: 10.1186/s13062-024-00497-8.


Strategies for Engineering of Extracellular Vesicles.

Danilushkina A, Emene C, Barlev N, Gomzikova M Int J Mol Sci. 2023; 24(17).

PMID: 37686050 PMC: 10488046. DOI: 10.3390/ijms241713247.


p53 Affects Zeb1 Interactome of Breast Cancer Stem Cells.

Parfenyev S, Shabelnikov S, Tolkunova E, Barlev N, Mittenberg A Int J Mol Sci. 2023; 24(12).

PMID: 37372954 PMC: 10297930. DOI: 10.3390/ijms24129806.


References
1.
Chang Y, Graves B, Guerlavais V, Tovar C, Packman K, To K . Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A. 2013; 110(36):E3445-54. PMC: 3767549. DOI: 10.1073/pnas.1303002110. View

2.
Grossi E, Sanchez Y, Huarte M . Expanding the p53 regulatory network: LncRNAs take up the challenge. Biochim Biophys Acta. 2015; 1859(1):200-8. DOI: 10.1016/j.bbagrm.2015.07.011. View

3.
Lauriola L, Granone P, Ramella S, Lanza P, Ranelletti F . Expression of the RNA-binding protein HuR and its clinical significance in human stage I and II lung adenocarcinoma. Histol Histopathol. 2012; 27(5):617-26. DOI: 10.14670/HH-27.617. View

4.
Kussie P, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine A . Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996; 274(5289):948-53. DOI: 10.1126/science.274.5289.948. View

5.
Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View